Proteins and Peptides

14 Mar 2007 Ambrilia and Mallinckrodt Announce IND Filing for Phase III Clinical Study of Improved Octreotide Formulation
14 Mar 2007 Maxygen Announces End of Co-Development Agreement
13 Mar 2007 Cangene Receives an Approvable Letter From the FDA for Human Growth Hormone
13 Mar 2007 Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase IB/II Clinical Trial in Late Stage Cancer Patients
10 Mar 2007 Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
09 Mar 2007 Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies
09 Mar 2007 Alba Announces Completion of Enrollment and Dosing of Patients in Phase II Clinical Trial of AT-1001 for the Treatment of Celiac Disease
08 Mar 2007 ZymoGenetics Provides Update on rhThrombin Development Plans
08 Mar 2007 Allon product AL-108 successful in Phase Ib clinical trial
07 Mar 2007 Clinquest Group and TNO sign licensing agreement on protein for inflammatory disorders
07 Mar 2007 AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
07 Mar 2007 Nautilus Biotech and HanAll Pharmaceutical announce license agreement to develop three Nautilus Biotech products in South Korea
06 Mar 2007 Cytheris Releases Promising Clinical Data on its Interleukin-7 Immune Enhancer at the 2007 CROI Meeting in Los Angeles
06 Mar 2007 Transition Therapeutics Announces Positive Data from E1-I.N.T.(TM) Clinical Trials in Type 1 and Type 2 Diabetes Patients
06 Mar 2007 InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
03 Mar 2007 GTC Biotherapeutics Enters Into Process Development And Clinical Supply Manufacturing Services Agreement With Pharmathene For Protexia
02 Mar 2007 Biolex Therapeutics Researchers Present Preclinical Data for Direct-Acting Thrombolytic BLX-155 at Scientific Conference
02 Mar 2007 Levemir(R) approved in Europe for use in combination with oral antidiabetic drugs
02 Mar 2007 Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
02 Mar 2007 Kamada begins phase III clinical trial in the U.S. with its Alpha-1 Antitrypsin product indicated for Congenital Emphysema
28 Feb 2007 Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
28 Feb 2007 Nautilus Biotech announces IND filing for Belerofon, its oral, long-lasting, Interferon-alpha drug
28 Feb 2007 Jerini Plans to Submit US New Drug Application in Third Quarter 2007 for Icatibant in Hereditary Angioedema
28 Feb 2007 Human Genome Sciences Announces Positive Interim Results Of Phase 2B Trial Of Albuferon(R) With Ribavirin In Treatment-Naïve Patients With Chronic Hepatitis C
28 Feb 2007 Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) With Ribavirin In Treatment-Naïve Patients With Chronic Hepatitis C Genotypes 2 And 3

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up